Jiasen Xie

Title: Jiasen Xie: Innovator in Cancer Research

Introduction

Jiasen Xie is a prominent inventor based in Beijing, China. He has made significant contributions to the field of cancer research through his innovative patent. His work focuses on advanced techniques for sequencing and predicting antigen epitopes, which are crucial for developing targeted therapies.

Latest Patents

Jiasen Xie holds a patent for the LRFFT2 cell. This patent describes methods that utilize human peripheral blood for circulating tumor DNA (ctDNA) sequencing or tumor tissues for whole exome sequencing. The process involves screening mutation sites to perform antigen epitope prediction and synthesizing expression gene sequences of mutant peptides. Additionally, the patent outlines the construction of a lentiviral vector, which is used to transfect antigen-presenting cells (APCs) and transform common T cells into RFF cells. The suppressive signaling molecules identified in his research include PD-1, Tim-3, LAG3, CTLA-4, BTLA, VISTA, CD160, and 2B4 (CD244).

Career Highlights

Throughout his career, Jiasen Xie has worked with Beijing Dcty Biotech Co., Ltd. His expertise in biotechnology and cancer research has positioned him as a valuable contributor to the field. His innovative approaches have the potential to enhance cancer treatment strategies significantly.

Collaborations

Jiasen Xie has collaborated with notable professionals in his field, including Shunchang Jiao and Rong Zhang. These collaborations have further enriched his research and development efforts.

Conclusion

Jiasen Xie's contributions to cancer research through his innovative patent demonstrate his commitment to advancing medical science. His work has the potential to impact the future of cancer therapies significantly.